C12N 2730/10022
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2730/10022 (New viral proteins or individual genes, new structural or functional aspects of) appears on 3 US grants and 10 published applications in this corpus.
Search patents in C12N- Granted patents
- 3
- Published applications
- 10
- Assignees
- 9
- Inventors
- 14
- Latest grant
- 28 Aug 2018
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2008 | 0 | 1 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 1 | 3 |
| 2012 | 0 | 0 |
| 2013 | 1 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 1 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 2 |
| 2023 | 0 | 0 |
| 2024 | 0 | 1 |
| 2025 | 0 | 0 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Vaccine combinations28 Aug 2018US 10,058,605 B2Bharat Biotech International Limited
- SARS vaccine compositions and methods of making and using them13 Aug 2013US 8,506,968 B2Eli Lilly and Company
- Hepatitis virus core proteins as vaccine platforms and methods of use thereof8 Feb 2011US 7,883,843 B2Vaccine Research Institute of San Diego
- Hepatitis B Virus Receptor OATP and Use Thereof21 May 2026US 2026/0137774 A1Shanghai Hep Pharmaceutical Co., Ltd.
- Rnai agent for inhibiting hbv expression and use thereof18 Apr 2024US 2024/0124879 A1OliX Pharmaceuticals, Inc.
- Hybrid virus-like particles and use thereof as a therapeutic hepatitis b vaccine29 Dec 2022US 2022/0411475 A1VLP Biotech, Inc.
- Conformational epitope of hepatitis b surface antigen and antibody binding specifically thereto14 Apr 2022US 2022/0112246 A1The Green Cross Corporation
- Vaccine combinations21 Jan 2016US 2016/0015804 A1Bharat Biotech International Limited
Most cited
By later US patents